Please try another search
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Name | Age | Since | Title |
---|---|---|---|
Thomas Kuhn | - | 2009 | Co-Founder, CEO & Director |
Harold E. Lebovitz | - | - | Member of Scientific Advisory Board |
Mohammed Khoso Baluch | - | 2012 | Independent Chairman of the Board |
Kohjiro Ueki | - | - | Member of Scientific Advisory Board |
Pascale Boissel | 57 | 2015 | Independent Director |
Masato Kasuga | - | 2019 | Member of Scientific Advisory Board |
Richard N. Kender | 67 | 2015 | Independent Director |
Kenneth Cusi | - | 2019 | Member of Scientific Advisory Board |
Marc Engelen | - | 2021 | Member of Scientific Advisory Board |
Stephan Kemp | - | 2021 | Member of Scientific Advisory Board |
Keith van Haren | - | 2021 | Member of Scientific Advisory Board |
Ralph A. Defronzo | - | 2019 | Member of Scientific Advisory Board |
Edouard Guillet | - | 2022 | Observer to the Board of Directors |
Philip Newsome | - | 2021 | Member of the Scientific Advisory Board |
Hirotaka Watada | - | - | Member of Scientific Advisory Board |
Vlad Raziu | - | 2020 | Member of the Scientific Advisory Board |
S. Ali Fatemi | - | 2021 | Member of Scientific Advisory Board ? |
Stephen A. Harrison | - | 2019 | Member of Scientific Advisory Board |
Quentin Anstee | - | 2020 | Member of the Scientific Advisory Board |
Arun J. Sanyal | - | 2020 | Member of the Scientific Advisory Board |
John F. Amatruda | - | - | Member of Scientific Advisory Board |
Wataru Ogawa | - | - | Member of Scientific Advisory Board |
Fanny Mochel | - | 2021 | Member of Scientific Advisory Board |
Jaspreet Singh | - | 2021 | Member of Scientific Advisory Board |
Kohei Kaku | - | 2019 | Member of Scientific Advisory Board |
Gregory Steinberg | - | 2020 | Member of Scientific Advisory Board |
Florian Eichler | - | 2021 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review